Mounjaro vs. Zepbound: label differences and cost checks

The brand name completes the product identity

Mounjaro and Zepbound contain tirzepatide, but the shared ingredient does not complete the product identity. Their FDA labels name different indications and presentations, and each commercial fact belongs to the exact brand and package. This source set includes a dated Mounjaro list price but no current Zepbound price. Leave that field open rather than borrowing a stale or unsupported number.

This distinction keeps searches, benefit checks, and receipts aligned. An ingredient-only note can lose the exact brand requested by a plan, quoted by a pharmacy, or shown on a carton. Record Mounjaro and Zepbound in separate checklist rows even when both rows say tirzepatide. The purpose is administrative accuracy: a source for one branded product should not silently become evidence for the other. The cited evidence does not extend that identity observation into a medical comparison.

The cited Mounjaro prescribing information states that Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Each part belongs in the record: the adjunct language, glycemic-control purpose, type 2 diabetes population, and age boundary. Shortening the statement to a broad ingredient category removes information that the FDA label expressly supplies.

The same cited label doesn't list chronic weight management as a Mounjaro indication. That is a label-scope observation, not a comment about outcomes or an invitation to use the product outside the label. A content page, quote, or coverage inquiry should not describe Mounjaro as FDA-approved for chronic weight management on the strength of tirzepatide's presence in another brand. Keep the product name attached to the precise indication statement every time it is summarized.

How the cited FDA indications differ

The cited Zepbound label states that Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. The population conditions and accompanying diet-and-activity language are part of the FDA wording and should remain visible in an exact summary.

That label also lists treatment of moderate to severe obstructive sleep apnea in adults with obesity, again in combination with a reduced-calorie diet and increased physical activity. This is a separate labeled indication with its own condition and adult-population boundary. A faithful comparison reports both Zepbound indications without ranking them against Mounjaro's diabetes indication. These are label categories, not head-to-head measures, and the sources used here support no broader conclusion.

An FDA indication identifies the use and population described in that product's approved prescribing information. It is therefore useful for naming the product correctly, preparing a benefit inquiry, and checking whether a marketing statement matches the cited label. Here, the labels show a diabetes glycemic-control indication for Mounjaro and long-term weight-reduction plus obstructive-sleep-apnea indications for Zepbound. That is the complete comparison drawn from the indication sections.

The indication text doesn't create a result forecast, a ranking, or a household cost. It also doesn't answer a personal clinical question. The scope deliberately omits trial outcomes, adverse-event comparisons, administration schedules, and individual factors. Those topics would move beyond the assigned product-identity scope. For an evidence file, quote the label narrowly, identify its revision, and avoid replacing its population language with a looser description based only on the active ingredient.

The labeled presentations are not the same

The Mounjaro label describes a clear, colorless to slightly yellow injection supplied in prefilled single-dose pens or single-dose vials. It lists six presentation strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL. These details belong to product and package identification. They are reproduced to help match records, not to provide administration instructions.

A pharmacy quote should identify more than Mounjaro or tirzepatide. Capture pen or vial, labeled strength, volume, count, days represented by the quote, and the pharmacy or direct channel. The official price page defines its cited fill as four pens and one month's supply. If a quote concerns a different quantity or presentation, place it on another row. Do not normalize unmatched packages into one per-fill figure without documenting the conversion and source.

The cited Zepbound label describes a clear, colorless to slightly yellow injection in prefilled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens. Single-dose pens and vials are listed at six strengths from 2.5 mg/0.5 mL through 15 mg/0.5 mL. Multi-dose vials and KwikPens contain four labeled portions and use presentation-specific total volumes and concentrations. This is package identity, not administration guidance.

Presentation names matter because a manufacturer program, pharmacy quote, supply record, or benefit claim can be limited to one package type. Write the exact name shown in the current source rather than reducing all options to pen or injection. If the available Zepbound record doesn't state whether it is a single-dose pen, single-dose vial, multi-dose vial, or KwikPen, mark presentation as Not stated and obtain a product-specific quote before comparing amounts.

Tie each quote to a brand, package, and date

Build the key in a fixed order: brand, active ingredient, FDA label revision, dosage form, presentation, labeled strength, volume, package count, and transaction channel. Add the National Drug Code from the actual package or claim when available, but don't invent it from a neighboring presentation. The cited sources for this check don't enumerate those codes, so the checklist field remains Not stated until a pharmacy, package, or plan record supplies it.

Then match the same key across the prescription record, carton, pharmacy quote, benefit response, manufacturer terms, checkout, and receipt. A mismatch doesn't prove an error, but it prevents a clean comparison until explained. For example, a four-pen Mounjaro fill and a Zepbound multi-dose presentation should not share an unlabeled quantity field. Keep source dates beside each field because labels, packages, prices, and program rules can change on different schedules.

What the available Mounjaro price supports

On 2026-07-23, Lilly's official pricing page stated a Mounjaro list price of $1,112.16 per fill. The page defined one fill as a month's supply consisting of four pens. It also explained that list price is wholesale acquisition cost, the amount Lilly charges wholesalers, and that pharmacy payment can differ. The date, product, four-pen quantity, per-fill term, and list-price category must accompany the number wherever it appears.

That $1,112.16 figure is not a universal checkout amount. Lilly states that actual payment depends largely on prescription-drug insurance, pharmacy charges, discounts, or assistance. Treat it as one dated reference row labeled list price. A pharmacy cash quote belongs on another row, an insured responsibility on another, and any savings result on another. Combining them under cost hides the transaction lane and makes later verification impossible.

The three cited sources are the two FDA labels and the official Mounjaro pricing page. They don't state a current Zepbound list price, cash price, or manufacturer-program amount for this check. The correct Zepbound price entry is therefore Not stated, not a remembered figure, a search snippet, or a number imported from another product page. This evidence gap blocks a numerical Mounjaro-versus-Zepbound price verdict.

To refresh the missing field, identify an authorized first-party Zepbound price source and record its check date, exact presentation, strength, package count, channel, insurance status, offer name, term, cap, duration, and change rights. Until that evidence is accepted, use the guide for identity and verification structure only. A missing amount is not zero, unavailable, or necessarily higher. It simply means the cited sources do not establish the number.

Leave the Zepbound price blank until it is sourced

The Mounjaro pricing page says commercially insured patients may be eligible for a savings card and that people without insurance or without Mounjaro coverage may have separate self-pay savings options. Those statements describe possible lanes, not approval or a final amount. Government and commercial insurance categories can have different rules. A card, assistance inquiry, pharmacy discount, and plan benefit determination should occupy separate checklist rows with their own evidence dates.

For coverage, ask the plan about the exact brand and presentation, formulary status, applicable criteria, required documentation, pharmacy network, deductible position, cost-sharing structure, and the response's effective date. Record what the plan actually says rather than inferring from another tirzepatide brand. For self-pay, retain the official offer name, eligible channel, package, amount, expiration, and restrictions. Neither path guarantees stock, continued terms, or a particular household payment.

Keep coverage and savings outside the label comparison

Give Mounjaro and Zepbound separate columns. Add rows for active ingredient, exact FDA indications, label revision, form, presentation, strength, volume, package quantity, dispensing channel, list price, pharmacy cash quote, insured responsibility, savings program, self-pay program, offer end date, monthly or per-fill cap, and source check date. Enter Not stated whenever the authorized evidence doesn't answer a row. Do not copy a value across columns merely because the ingredient matches.

For each price entry, preserve the amount due today and the amount expected at the next comparable fill. Save the plan or pharmacy response, offer terms, pre-payment summary, and receipt. If the quoted presentation changes, create a new row rather than overwriting the old identity. The checklist should make one conclusion easy to audit: which exact product and package was priced, through which channel, under which coverage or self-pay lane, on what date.

The first error is treating tirzepatide as the full product name. The second is describing Mounjaro with Zepbound's labeled uses or reducing Zepbound's two indication statements to a generic weight label. The third is calling every injector a pen and dropping whether the record concerns a single-dose or multi-dose presentation. Each shortcut removes a field that the cited labels provide and can disconnect the article from a package or claim.

Commercial errors are equally predictable: treating list price as the pharmacy bill, calling a possible savings path coverage, comparing different package quantities, omitting the check date, or filling an unsupported Zepbound price with a stale number. Avoid a cheapest-brand conclusion when one side is Not stated. Its defensible result is a clean label and identity map plus a repeatable process for obtaining product-specific commercial evidence.

Finish with a two-column evidence record

The source check is dated 2026-07-23. The FDA documents support indication and presentation claims; the pricing page supports Mounjaro's list-price and payment-lane statements. No source in the assigned set supports an exact current Zepbound price, so none is published here.

Product pages, labels, program terms, plan responses, and pharmacy quotes can change after the source check. Re-run the identity and commercial checklist with current documented evidence before relying on any amount or coverage status.